Severe and disabling joint pain has been connected to the use of dipeptidyl peptidase-4 inhibitors and combination therapies for diabetes, prompting a new FDA warning…
Search results for: bone mineral density
New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising
The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…
Risk of Hearing Loss in Patients with Osteoporosis
People diagnosed with osteoporosis have almost twice the risk of developing hearing loss as those without the bone-fragile skeletal disease, according to results from a large retrospective study in Taiwan. The study looked at the risk of sudden sensorineural hearing loss (SSHL) using data collected from Taiwan’s National Health Insurance claims and is believed to…
EULAR 2015: Role of ACPA Positivity in Osteoarthritis
ROME, Italy—The role of ACPA positivity in osteoarthritis is coming more into focus, with results from recent studies by researchers in Germany showing that ACPA positivity apparently works in concert with rheumatoid factor positivity to enhance bone erosion and that ACPA-positive patients show signs of bone erosion before they have clinical signs of arthritis. The…
Serum IGF-1 Tied to Fracture Risk in Elderly Women
NEW YORK (Reuters Health)—A Dutch study confirms that reduced serum levels of insulin-like growth factor-1 (IGF-1) are associated with increased fracture risk in elderly women, but not men. In an Aug. 31 online paper in the Journal of Clinical Endocrinology & Metabolism, Dr. N.C. van Varsseveld, of VU University Medical Center, Amsterdam, and colleagues noted that…
Growth Hormone Reduces Fractures in Women with Osteoporosis
NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…
Teriparatide to Denosumab Switch Helpful in Osteoporosis
NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…
HIV Infection: What Rheumatologists Need to Know
It has been nearly 35 years since the original descriptions of what now is recognized as AIDS (the acquired immune deficiency syndrome), an advanced form of infection secondary to the human immunodeficiency virus (HIV). The epidemic of HIV infection remains the singular most dramatic epidemic of our generation and will likely remain with us for…
2014 ACR/ARHP Annual Meeting: Rheumatologic Research Uncovers Clues to Therapies
Studies explore role of STING pathway in bone remodeling, denosumab to reduce fracture risk, autotaxin’s role in fibrosis, SSc
Atypical Fractures Associated with Bisphosphonates
Plus, FX006, odanacatib and other rheumatology drug news, safety updates
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »